CALLABLE MULTI DEFENDER VONTI - NOVO-NORDISK B/ELI LILLY & CO CALLABLE MULTI DEFENDER VONTI - NOVO-NORDISK B/ELI LILLY & CO Share Price
Certificat
RMBUPV
CH1300254328
| Market Closed - Swiss Exchange 16:20:00 15/05/2024 BST | ||
| 106 USD | +0.28% |
|
| Current month | +0.47% | ||
| 3 months | -0.19% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 15/05/24 | 106 | +0.28% |
Delayed Quote Swiss Exchange
Last update May 15, 2024 at 04:20 pm
More quotesStatic data
| Product type | Reverse Convertibles |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| RMBUPV | |
| ISIN | CH1300254328 |
| Date issued | 08/12/2023 |
| Strike | 598 $ |
| Maturity | 10/06/2025 (389 Days) |
| Parity | 0.6 : 1 |
| Emission price | 100 $ |
| Emission volume | N/A |
| Settlement | both |
| Currency | USD |
Technical Indicators
| Highest since issue | 106.7 $ |
|---|---|
| Lowest since issue | 99.5 $ |
| Spread | 17 $ |
| Spread % | 1.59% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
770
USD
Average target price
850.4
USD
Spread / Average Target
+10.44%
- Stock Market
- Certificates
- RMBUPV Certificat
